ReviewCurrent opinion in ophthalmology2018
Cytokines in uveitis.
Review in Current opinion in ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Psoriasis and uveitis.International ophthalmology · 2022Pooled it
- Natural Products Targeting Immune Mechanisms in Ocular Inflammation: Uveitis and Dry Eye.Current issues in molecular biology · 2026Review
- Aptamers Targeting IL17A and Its Receptor Suppress IL17 Signaling in Different Cell Types.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Ocular complications in psoriasis and psoriatic arthritis.Reumatologia · 2026Review
- Do the monocyte-derived dendritic cells exert a pivotal role in the early onset of experimental autoimmune uveitis?BMC ophthalmology · 2025Article
- Aqueous Humor Cytokine Profiling Reveals Distinct Roles for Serum Amyloid A, Interleukin-8, and Endothelin-1 in Pseudoexfoliation Syndrome and Glaucoma.International journal of molecular sciences · 2025Article
- Genetics of Circulating Inflammatory Proteins and Iridocyclitis: An Exploratory Mendelian Randomization Study.Translational vision science & technology · 2025Article
- Secukinumab in refractory non-infectious anterior uveitis.Frontiers in ophthalmology · 2025Article
- Network pharmacology and molecular docking analyses of the Wuwei Mingmu formula indicate that IL-10 and IL-6 are critical targets against experimental autoimmune uveitis in rats.Frontiers in pharmacology · 2025Article
- Integrative immunology identified interferome signatures in uveitis and systemic disease-associated uveitis.Frontiers in immunology · 2025Article
- Review
- Immunoregulatory Properties of Immune Cells that Associate with the Lens Capsule Surface during Acute and Resolution Phases of Experimental Autoimmune Uveitis.The American journal of pathology · 2024Article
- Intraocular Immune Response in Human Uveitis: Time to Look Beyond Animal Models.American journal of ophthalmology · 2024Review
- Trends and hot spots in research related to aqueous humor from 2014 to 2023: A bibliometric analysis.Heliyon · 2024Article
- Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases.Translational vision science & technology · 2024Article
- Development of Clarstatin, a Novel Drug Lead for the Therapy of Autoimmune Uveitis.Pharmaceutics · 2024Article
- The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.Frontiers in pharmacology · 2024Review
- Involvement of the systemic microcirculation in pediatric uveitis.Pediatric rheumatology online journal · 2023Article
- Serum antiretinal antibodies and cytokine profiling in autoimmune retinopathy and their association with clinical outcomes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewIncreasing evidence supports Th17 cells as key mediators of ocular inflammatory disease. Cytokines that are important for the development and pathologic function of these cells are potential therapeutic targets in patients with immune mediated uveitis. This review provides an overview of these cytokines including recent insights about their roles in ocular inflammation from laboratory and clinical studies. RECENT
findingsInterleukin (IL)-6, IL-10, IL-17, IL-22, IL-23 and tumour necrosis factor-alpha (TNFα) are cytokines that have been examined for their functional role in uveitis and their relationship to pathologic Th17 cells. Studies in animal models, particularly in experimental autoimmune uveitis (EAU), have been instrumental in studying the role of these cytokines in disease pathogenesis. More recently, studies on aqueous, vitreous and serum from patients with uveitis using flow cytometry and multiplex ELISA bead-based methodologies have provided insights into the contribution of Th17 cells and the related cytokines in ocular inflammatory diseases. The central role of IL-23 in determining the pathologic Th17 fate has made it an effective therapeutic target in systemic diseases such as psoriasis and thereby an attractive potential target for patients with immune-mediated uveitis. SUMMARY: Th17 cells, and their related cytokines, are important inflammatory mediators in autoimmune uveitis. Animal and human studies continue to provide new information to direct development of new cytokine-targeted therapies for patients with uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.